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Novel mutations of CHST6 in Iranian patients with macular
corneal dystrophy
Purpose: To characterize mutations within the carbohydrate sulfotransferase 6 (CHST6) gene in Iranian subjects from 12
families with macular corneal dystrophy (MCD).
Methods: Genomic DNA was extracted from peripheral blood of 20 affected patients and 60 healthy volunteers followed
by polymerase chain reaction (PCR) and direct sequencing of the CHST6 coding region. The observed nucleotide
sequences were then compared with those found by investigators in other populations with MCD and in the controls.
Results: Analysis of CHST6 revealed 11 different mutations. These mutations were comprised of six novel missense
mutations (p.F55L, p.P132L, p.S136G, p.C149Y, p.D203Y, and p.H249R), one novel nonsense mutation (p.S48X), one
novel frame shift (after P297), and three previously reported missense mutations (p.P31L, p.C165Y, and p.R127C). The
majority of the detected MCD mutations are located in the binding sites or the binding pocket, except the p.P31L and
p.H249R mutations.
Conclusions: Nucleotide changes within the coding region of CHST6 are predicted to significantly alter the encoded
sulfotransferase within the evolutionary conserved sequences. Our findings show that CHST6 mutations are responsible
for the pathogenesis of MCD in Iranian patients. Moreover, the observation that some cases of MCD cannot be explained
by mutations in the coding region of CHST6 suggests that MCD may result from possible upstream rearrangements in the
CHST6 genomic region.
Corneal  dystrophies  are  a  heterogeneous  group  of
disorders that may lead to severe visual impairment of which
macular  corneal  dystrophy  (MCD;  OMIM  217800)  is
transmitted as an autosomal recessive trait [1]. The prevalence
of MCD varies immensely in different parts of the world, but
in most populations, the condition is rare. As a treatment,
penetrating keratoplasty is performed when useful vision has
been lost. Reportedly, in Iceland and Japan, MCD accounts
for 75% and 10%, respectively, of the corneal dystrophies
requiring corneal grafting [2,3]. Clinical symptoms usually
manifest within the first decade of life, and MCD patients
show  spotted  opacity  in  both  corneas.  These  abnormal
deposits  are  associated  with  a  central  stromal  haze  that
gradually extends to the periphery of the cornea, leading to
visual impairment, and patients require keratoplasty [4]. MCD
has been subdivided into three immunophenotypes (MCD
types I, IA, and II) based on the reactivity of the patient's
serum and corneal tissue to monoclonal anti-keratan sulfate
antibody (5D4 anti-KS antibody) [5].
Biochemical  studies  have  indicated  that  a  specific
sulfation step of keratan sulfate is impaired in MCD, resulting
in an accumulation of glycosaminoglycans (GAGs). Keratan
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sulfate proteoglycan, the most abundant carbohydrate in the
cornea, plays an important role in maintenance of corneal
transparency [6,7]. Keratan sulfate consists of a linear poly-
N-acetyllactosamine chain that carries sulfate residues on C-6
of  N-acetylglucosamine  (GlcNAc)  and  galactose  (Gal).
Because  the  sulfation  of  carbohydrates  affects  their
biochemical  characteristics  such  as  water  solubility  and
electrical charge, this modification appears to be important for
the function of keratan sulfate proteoglycans in the cornea.
Considering the importance of the sulfated carbohydrates of
keratan sulfate in the normal function of the cornea, it has been
suggested that lack of this sulfation step is a major cause of
MCD [6,8,9].
It has also recently been shown that there is a failure in
the  activity  of  corneal  GlcNAc  6-O-sulfotransferase  (C-
GlcNAc6ST), which transfers sulfate to position 6 of GlcNAc
residues  and  this  enzyme  participates  in  biosynthesis  of
corneal keratan sulfate proteoglycan. In the cornea of patients
with MCD, a decrease in C-GlcNAc6ST activity results in the
formation of poorly sulfated or non-sulfated keratan sulfate
and causes corneal opacity [10,11].
Using genetic linkage analysis, the critical region for
MCD  has  been  mapped  to  chromosome  16  (16q22).  The
carbohydrate sulfotransferase 6 gene (CHST6) was identified
within the MCD critical region encoded C-GlcNAc6ST, and
mutations in CHST6 have been shown to be the fundamental
defect in MCD [12,13].
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and Biotechnology, Tehran IranIn the present study, which is the first comprehensive
work studying Iranian subjects with MCD, we screened 20
patients with MCD from 12 families to search for mutations in
CHST6.  We  identified  seven  novel  mutations  and  four
previously reported disease-causing mutations.
METHODS
Patients: This study was performed in accordance with the
Declaration of Helsinki and with the approval of the ethics
board of the Amiralmomenin Hospital and Guilan University
(Rasht,  Iran).  Twenty  patients  from  12  unrelated  Iranian
families  who  received  clinical  diagnosis  of  MCD  were
included  in  this  study.  Diagnosis  for  MCD  in  affected
individuals  was  made  by  cornea  specialists  at  the
Amiralmomenin Hospital (associated with Guilan University
of Medical Sciences). All patients were older than 25 years,
and the obtained pedigrees were consistent with an autosomal
recessive  inheritance  pattern.  There  was  not  any  known
consanguinity  in  the  patients'  families.  Sixty  unrelated,
unaffected, and healthy volunteers were recruited to serve as
controls.
Blood samples were obtained from a peripheral blood
vessel from affected patients and healthy volunteers. Genomic
DNA was extracted by standard procedure using the PAX
gene blood DNA kit (Qiagen, Valencia, CA).
DNA analysis: The coding region of CHST6 was amplified
using  polymerase  chain  reaction  (PCR)  and  the  primers
designed  to  create  three  overlapping  amplicons.  The
oligonucleotide primers used were identical to those reported
by Akama and associates [12].
Each  reaction  was  performed  in  a  50-µl  volume
comprising  of  genomic  DNA  (100  ng),  10X  PCR  buffer,
0.2 µM dNTP, 1.5–2 µM of MgCl2, 0.2 µM of each primer, 1
U of Taq DNA polymerase (Qiagen). The thermal cycling was
performed using the following protocol 2 min at 96 °C and 35
cycles of 30 s at 96 °C, 30 s at 57 °C, 45 s at 72 °C, and final
extension 7 min at 72 °C followed by a 4 °C hold cycle.
The PCR products were then purified using the QIAquick
PCR purification kit (Qiagen) and sequenced on both strands
by the ABI BigDye terminator chemistry and an ABI Prism
3700  instrument  (Applied  Biosystems,  Foster  City,  CA).
Sequences  were  analyzed  using  the  Sequencher  software
(Gene Codes Corporation, Ann Arbor, MI) and compared
with the nucleotide sequence of the CHST6 human cDNA
(GenBank accession number AF219990).
RESULTS
A  total  of  20  affected  patients  representing  12  different
families were enrolled in the study. The most abnormalities
found in this study were single base changes in the coding
region of CHST6 that altered a coded amino acid (Table 1),
seven of which were homozygous. The nucleotide changes
included  c.92C>T,  c.143C>A,  c.165C>A,  c.379C>T,  c.
406A>G, and c.746A>G, resulting in a proline to a leucine
substitution  (p.P31L),  a  serine  to  stop  codon  substitution
(p.S48X), a phenylalanine to a leucine substitution (p.F55L),
an arginine to a cysteine substitution (p.R127C), a serine to a
glycine (p.S136G), and a histidine to an arginine substitution
(p.H249R).
In family C, an insertion of a single base pair between
nucleotides 891 and 892 was identified, resulting in a frame
shift after codon, P297 (p.P297fs).
In addition, a compound heterozygosity was detected in
family E. In this family, a heterozygous changes, c.395C>T
and c.494G>A, was identified, predicting amino acid changes
of  proline  to  leucine  (p.P132L)  and  cysteine  to  tyrosine
(p.C165Y).
In  two  families,  only  one  heterozygous  pathogenic
change  was  observed  in  the  coding  CHST6  sequence.  In
family F, we found c.446G>A, which replaces a cysteine to a
tyrosine  (p.C149Y).  In  family  H,  c.607G>T  was  found,
replacing an aspartic acid to a tyrosine (p.D203Y). 
In the last two families (K and L), no presumable pathogenic
change was detected. In addition, a single novel nucleotide
TABLE 1. CHST6 MUTATIONS IN IRANIAN PATIENTS WITH MCD.
Family Number of patients Zygosity Nucleotide change Protein change Disease-causing or not
A 3 Homozygous c.746A>G p.H249R +
B 3 Homozygous c.92C>T p.P31L +
C 2 Homozygous c.891–892insC p.P297fs +
D 1 Homozygous c.143C>A p.S48X +
E 4 Heterozygous c.494G>A p.C165Y +
Heterozygous c.395C>T p.P132L +
F 1 Heterozygous c.446G>A p.C149Y +
G 1 Homozygous c.379C>T p.R127C +
H 1 Heterozygous c.607G>T p.D203Y +
I 1 Homozygous c.406A>G p.S136G +
J 1 Homozygous c.165C>A p.F55L +
K 1 Heterozygous c.405C>T - -
L 1 No mutations - - -
In the table “+” denotes that the observed changes are Disease-causing, and “-” denotes that the observed changes are not
Disease-causing.
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374polymorphism,  c.405C>T  (a  heterozygous  change),  was
found  in  family  K.  It  was  considered  a  non-pathogenic
sequence variant because it had no effect on the amino acid.
The amplified PCR products from 60 control individuals
were analyzed for each alteration using direct sequencing,
none of which indicated the mutations seen for the patients.
DISCUSSION
In this study, we examined the CHST6 coding region for
mutations  in  20  individuals  with  MCD  from  12  Iranian
families. Sequencing analysis revealed six novel missense
mutations (p.F55L, p.P132L, p.S136G, p.C149Y, p.D203Y,
and p.H249R), one nonsense mutation (p.S48X), one frame
shift  (p.P297fs),  and  three  previously  reported  missense
mutations (p.P31L [13], p.C165Y [14], and p.R127C [15]) in
CHST6 in the Iranian patients with MCD.
CHST6  encodes  the  C-GlcNAc6ST,  comprising  395
amino acids. This enzyme is localized in the Golgi apparatus
and  is  a  member  of  the  Gal/GalNAc/GlcNAc  6-O
sulfotransferase (GST) family. The C-GlcNAc6ST contains a
short  cytosolic  tail  at  the  NH2-terminal,  a  single
transmembrane  span,  and  a  COOH-terminal  domain  that
contains two putative binding sites for the high energy sulfate
donor (adenosine3′-phosphate-5′phosphosulfonate [PAPS]).
One of the binding sites is the 5′-phosphosulfate binding site
(5′-PSB), corresponding to amino acid 49–56, and the other
is the RX7S 3′-phosphate binding site (3′-PB), corresponding
to amino acid 202–210 (Figure 1). The sequence between the
two binding sites is thought to contribute to a binding pocket
that  interacts  with  an  acceptor  (GlcNAc)  to  bring  it  into
apposition with the sulfate donor [16].
It  is  reported  that  mutations  of  these  binding  motif
sequences abolish the sulfotransferase activity in the case of
other  glycosaminoglycan  sulfotransferases,  indicating
important catalytic roles of these amino acid residues [17].
The identified mutation of p.F55L is located in the 5'-PSB
domain.  The  mutations  of  p.R127C,  p.P132L,  p.S136G,
p.C149Y, p.C165Y are located in the sequence between the
5'-PSB  domain,  and  the  3'-PB  domain.  The  mutation  of
p.D203Y  is  located  in  the  RX7S  sequence  for  the  3'-PB
domain.  Whereas  the  mutations  of  p.P31L,  p.H249R  are
neither located in the binding motifs nor in the binding pocket.
Amino acid changes at positions 203 and 249 have been
previously reported by Akama et al. [12] and Warren et al.
[18], respectively, but they are different from the mutations
identified in the present study. We have observed c.607G>T
causing  a  replacement  of  an  aspartic  acid  to  a  tyrosine
(p.D203Y) while in Japanese patients with MCD, a change at
nucleotide position 609 (c.609C>A) causes the replacement
of an aspartic acid to a glutamic acid at the same protein
position  (p.D203E)  [12].  In  Iranian  subjects,  a  change  at
nucleotide position 746 (c.746A>T) leads to the replacement
of a histidine to an arginine at position 249 of the protein
(p.H249R) while in Indian patients with MCD, Warren et al.
Figure 1. Amino acid sequence of C-GlcNAc6ST. This diagram shows the location of missense mutations in Iranian patients with MCD.
These mutations are marked by amino acid position using letters with blue arrowheads. Bold letters show the location of the 5′phosphosulfate
binding site (5′-PSB) and the 3′ phosphate binding site (3′-PB).
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histidine to a cysteine (p.H249C). The identified nonsense
coding  region  mutation  would  clearly  have  a  significant
impact  on  the  encoded  enzyme.  The  nonsense  mutation
(p.S48X)  would  result  in  a  premature  termination  of  the
encoded protein. Likewise, the insertion of one nucleotide (c.
891–892insC)  will  cause  a  reading  frame  shift.  It  is
noteworthy that the occurrence of frame shift and nonsense
mutations may lead to the elimination of the protein due to
nonsense-mediated decay of the mRNA (NMD).
NMD in mammalian cells generally degrades mRNAs that
terminate translation more than 50–55 nucleotides upstream
of a splicing-generated exon-exon junction [19,20]. NMD
downregulates  spliced  mRNAs  that  prematurely  terminate
translation so production of the potentially toxic truncated
proteins that they encode does not occur [21].
It is notable that previously only one patient of Iranian
origin with MCD was studied. Deletion of the whole open
reading frame was identified as the cause in this individual
[22]. Additional evidence to support our findings that the
sequence changes identified are responsible for producing
inactivation of the CHST6 gene product is provided by the fact
that no mutations were detected in the CHST6 coding region
from control individuals.
In one family (family L), there were no coding region
mutations, and in another family (family K), the nucleotide
change had no effect on protein phenotype. These cases of
MCD  can  not  be  explained  by  mutations  in  the  coding
sequence of CHST6, suggesting that MCD may result from
possible  upstream  rearrangements  such  as  the  promotor,
which is also part of CHST6 and has not been analyzed in the
present study. It is intriguing that such a large number and
wide variety of novel mutations were discovered throughout
the CHST6 coding sequence. This suggests that in contrast to
TGFBI (transforming growth factor, beta induced) with its hot
spots  for  corneal  dystrophy-associated  amino  acid
substitution, CHST6 does not demonstrate a highly conserved
number of disease-causing mutations [23].
In  summary,  we  identified  seven  novel  and  three
previously reported CHST6 mutations in our panel consisting
of 20 Iranian MCD patients from 12 families. Further analysis
of these mutations may help to achieve a clearer understanding
of the molecular events leading to the characteristic lesions of
MCD.
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